107 related articles for article (PubMed ID: 19681063)
41. Rituximab-induced hypersensitivity pneumonitis.
Tonelli AR; Lottenberg R; Allan RW; Sriram PS
Respiration; 2009; 78(2):225-9. PubMed ID: 18843175
[TBL] [Abstract][Full Text] [Related]
42. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
[TBL] [Abstract][Full Text] [Related]
43. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
[TBL] [Abstract][Full Text] [Related]
44. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
45. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
46. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
47. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
48. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
Byrd JC; Waselenko JK; Maneatis TJ; Murphy T; Ward FT; Monahan BP; Sipe MA; Donegan S; White CA
J Clin Oncol; 1999 Mar; 17(3):791-5. PubMed ID: 10071268
[TBL] [Abstract][Full Text] [Related]
49. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
50. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
[TBL] [Abstract][Full Text] [Related]
51. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.
Wu Y; Jia Y; Xu J; Shuai X; Wu Y
J Clin Pharm Ther; 2013 Jun; 38(3):249-53. PubMed ID: 23506410
[TBL] [Abstract][Full Text] [Related]
52. New therapies, new concerns: rituximab-associated lung injury.
Lands LC
Pediatr Nephrol; 2010 Jun; 25(6):1001-3. PubMed ID: 20195643
[No Abstract] [Full Text] [Related]
53. A Case of Interstitial Lung Disease Probably Related to Rituximab Treatment.
Calderazzo M; Rende P; Gambardella P; De Sarro G; Gallelli L
Drug Saf Case Rep; 2015 Dec; 2(1):8. PubMed ID: 27747720
[TBL] [Abstract][Full Text] [Related]
54. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?
Worch J; Makarova O; Burkhardt B
Cancers (Basel); 2015 Jan; 7(1):305-28. PubMed ID: 25643241
[TBL] [Abstract][Full Text] [Related]
55. Sai-rei-to-induced lung injury: a case report and brief review of the literature.
Komiya K; Ishii H; Ohama M; Uchida M; Tsubone T; Iwashita T; Miyajima H; Okabe E; Matsumoto T; Matsumoto B; Kadota J
Intern Med; 2012; 51(24):3421-5. PubMed ID: 23257532
[TBL] [Abstract][Full Text] [Related]
56. Acute Liver Failure Due to Echovirus 9 Associated With Persistent B-Cell Depletion From Rituximab.
Bajema KL; Simonson PD; Greninger AL; Çoruh B; Pottinger PS; Bhattacharya R; Liou IW; Jalikis FG; Fligner CL; Rakita RM
Open Forum Infect Dis; 2017; 4(3):ofx174. PubMed ID: 28948184
[TBL] [Abstract][Full Text] [Related]
57. [Clinical Analysis of Acute Lung Injury in 26 Cases of Diffuse Large B-Cell Lymphoma Treated with Rituximab Chemotherapy].
Zheng D; Dong F; Pang M; Zhao W; Tian L; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1919-1922. PubMed ID: 33283720
[TBL] [Abstract][Full Text] [Related]
58. Use of rituximab in paediatric nephrology.
Sinha R; Agrawal N; Xue Y; Chanchlani R; Pradhan S; Raina R; Marks SD
Arch Dis Child; 2021 Nov; 106(11):1058-1065. PubMed ID: 34112638
[TBL] [Abstract][Full Text] [Related]
59. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
[TBL] [Abstract][Full Text] [Related]
60. Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.
Farhat L; Dara J; Duberstein S; De A
Drug Saf Case Rep; 2018 May; 5(1):22. PubMed ID: 29752554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
